Published in:
01-03-2019 | Reports of Original Investigations
Effect of cultural background and healthcare environment on postoperative opioid requirement
Authors:
Alex H. Konstantatos, MBBS (Hons), FANZCA, Taidi Zhong, MD, Eldho Paul, BSc, MSc, PhD, Sharon Tsang, BSc, MB, ChB, PhD, Suming Tian, MD, Minjun Liu, Dip Nur, Yuyuan Liang, Dip Nur, Yuanyuan Tian, MB, MSc, PhD, Shina Qiao, Dip Nur, William K. K. Wu, BSc, PhD, FRCPath, Matthew T. V. Chan, MBBS, PhD, FANZCA, FHKCA, FHKAM
Published in:
Canadian Journal of Anesthesia/Journal canadien d'anesthésie
|
Issue 3/2019
Login to get access
Abstract
Purpose
The objective of this prospective observational study was to investigate the interactions between cultural background, healthcare environment, and postoperative pain experience.
Methods
We enrolled 128 Chinese patients living in rural mainland China and 134 patients in Hong Kong with a higher level of Western cultural influences (defined by educational attainment, place of residence, and ability to understand English). All patients had major abdominal surgery and received patient-controlled analgesia with intravenous morphine for postoperative pain relief. The primary endpoint was total opioid requirement up to 48 hr after surgery. Other measures included pain intensity, opioid-related side effects, and genetic markers for opioid responsiveness.
Results
The mean (95% confidence interval) cumulative opioid requirement, expressed as morphine equivalent, during the first 48 hr after surgery was significantly less in patients from mainland China (18.8 [15.7 to 22] mg) compared with patients from Hong Kong (42.0 [38.3 to 45.6] mg, P < 0.0001). In a multivariable analysis, opioid requirement was influenced by ethnicity, duration of surgery, and severity of pain upon admission to the postanesthetic care unit.
Conclusions
These results suggest that postoperative pain behaviours and opioid requirement may be influenced by cultural background and healthcare environment in two populations of Chinese descent.
Trial registration
Australian and New Zealand Clinical Trials Registry (ACTRN12614000601639); registered 6 May, 2014.